Current filters:

Biogen Idecdaclizumab

1 to 9 of 20 results

New entrants to multiple sclerosis market will drive 10% pa growth through 2018


The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif


US biotech firm Biogen Idec (Nasdaq: BIIB) saw its shares jump 6% to $107.53 last Friday, after the company…

AlemtuzumabBiogen IdecBiotechnologydaclizumabdimethyl fumarateGenzymeLemtradaNeurologicalPharmaceuticalResearchSanofi

Biogen Idec and Abbott MS drug candidate daclizumab positive in Ph IIb


US biotech Biogen Idec (Nasdaq: BIIB) and health care giant Abbott Laboratories (NYSE: ABT ) have announced…

Abbott LaboratoriesBiogen IdecBiotechnologydaclizumabNeurologicalPharmaceuticalResearch

Facet Biotech Stockholders reject Biogen Idec tender offer, so deal over


USA-based Biogen Idec’s fight to gain control of Facet Biotech came to an end last night, when the…

Biogen IdecBiotechnologydaclizumabMergers & AcquisitionsNeurologicalNorth AmericaOncologyPharmaceuticalZenapax

Biogen Idec ups offer 21% for Facet Biotech to $17.50 a share, which is again rejected by board


December 4, 2009 US biotechnology firm Biogen Idec is continuing its fight to gain control of Facet…

Biogen IdecBiotechnologydaclizumabMergers & AcquisitionsNeurologicalNorth AmericaOncologyPharmaceuticalZenapax

Facet Biotech says Biogen Idec’s offer undervalues the firm


Facet Biotech’s board of directors has reviewed Biogen Idec's unsolicited acquisition offer, made…

Biogen IdecdaclizumabNeurologicalNorth AmericaPharmaceuticalZenapax

Facet Biotech confirms hostile bid from Biogen Idec


Facet Biotech Corp has confirmed that it is in receipt of fellow USA-based Biogen Idec

Biogen IdecBiotechnologydaclizumabNeurologicalNorth AmericaOncologyZenapax

1 to 9 of 20 results



Back to top